icon-folder.gif   Conference Reports for NATAP  
61th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2010
Back grey_arrow_rt.gif
Antiviral Activity, Safety and Pharmacokinetics of IDX320, a Novel Macrocyclic HCV Protease Inhibitor, in a 3-Day Proof-of-Concept Study in Patients with Chronic Hepatitis C
  Reported by Jules Levin AASLD Nov 2 2010 Boston
H.W. Reesink1, J. de Bruijne1, A.A. van Vliet2, F. Muhr-Wilkenshoff 2, C. Weegink1, W. Mazur3, A. Wiercinska-Drapao4, K. Simon5, G. Cholewinska-Szymanska4, J. Kapocsi6, I. Varkonyi7, X.J. Zhou8, M.F. Temam8, J. Molles8, J. Chen8, K. Pietropaolo8, J.Z. Sullivan-Bolyai8 and D. Mayers8 1Academic Medical Center, Amsterdam, NL; 2Pharmaceutical Research Associates Group, Zuidlaren, NL and Berlin, Germany; 3Specialist Hospital, Chorzow, Poland; 4Hospital of Infectious Diseases, Warsaw, Poland; 5Provincial Specialist Hospital, Wrocaw, Poland; 6Semmelweis University, Budapest, Hungary; 7Infectious Disease Hospital, Debrecen, Hungary; 8Idenix Pharmaceuticals, Inc., Cambridge, MA, USA and Montpellier, France.

Values are reported as means±SD, except for Tmax where medians (min-max) are reported. For Ctrough, (min-max) is also shown; Ctrough is C24h for QD and C12h for BID.
# AUC is AUC0-24h for QD and AUC0-12h for BID; For BID, daily AUC0-24h (not shown) can be calculated as the sum of the AM and PM AUC.

1. Lallos LB, McCarville J, Li B, et al (2010). Journal of Hepatology 52 Suppl. 1 298-99
2. van de Wetering de Rooij J, Zhou XJ, Temam MF et al (2010). 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy. June 23rd, 2010; Boston, Massachusetts.